Reporting period: January 2014 – December 2014
The human immunodeficiency virus (HIV) epidemic in Myanmar is concentrated among men who have sex with men (MSM), people who inject drugs (PWID) and female sex workers (FSW). HIV prevalence in the adult population aged 15 years and older was esti...mated at 0.54% in 2014. But data from HIV Sentinel Sero-Surveillance (HSS) indicates higher prevalence in 2014 among key populations: FSW 6.3%, MSM 6.6% and PWID 23.1%. Compared to 2012 data, the prevalence has declined from 7.1% in FSW and 8.9% in MSM, but has increased from 18% in PWID.
Epidemiological modelling suggests that in 2014 there were around 212,000 people living with HIV (PLHIV) in Myanmar, 34% of whom were females. Nearly 11,000 people died of HIV-related illnesses, compared to approximately 15,000 in 2011. An estimated 9,000 new infections occurred in 2014.
more
2nd edition.
The practical aspects of TB patient care from the onset of symptoms to the completion of treatment are covered in this guide
BMC Public Health (2018) 18:668 https://doi.org/10.1186/s12889-018-5594-3
Q9: Antidepressant medicines in individuals with a depressive episode in bipolar disorder1Q9: In individuals presenting with a depressive episode in bipolar disorder, are antidepressant medicines effective and safe?
Q10: In individuals with psychotic disorders (including schizophrenia) and bipolar disorders are psychoeducation, family interventions and cognitive-behavioural therapy feasible and effective?
Материалы научно-практической конференции с международным участием «Достижения в нейробиологии и терапии болезни Альцгеймера», посвященной памяти профессора Э..... Штернберга (Москва, 6 декабря 2013 г.)
more
Accessed: 10.03.2019
mhGAP Training Manual for the mhGAP Intervention Guide for mental, neurological and substance use disorders in non-specialized health settings – version 2.0 (for field testing)
SADF POLICY BRIEF
31 October 2018 Issue n° 8
ISSN: 2406-5625
Update of the Mental Health Gap Action Programme
(mhGAP) Guideline for Mental, Neurological and Substance use Disorders May 2015
Harm Reducation, Decriminalization and Zero Discrimination for People who use Drugs
Introduction
Chapter A.10
Externalising disorders
Chapter D.2
Externalising disorders
Chapter D.3
Mood disorders
Chapter E.1
2015 edition
Mood disorders
Chapter E.2
Mood disorders
Chapter E.4
2018 edition
Substance use disorders
Chapter G.3